[New perspective of diagnosis and treatment of hepatocellular carcinoma complicated with portal vein tumor thrombosis].

S Y Peng, Y H Wang, Y Jin, J T Li
{"title":"[New perspective of diagnosis and treatment of hepatocellular carcinoma complicated with portal vein tumor thrombosis].","authors":"S Y Peng, Y H Wang, Y Jin, J T Li","doi":"10.3760/cma.j.cn112139-20240910-00419","DOIUrl":null,"url":null,"abstract":"<p><p>Hepatocellular carcinoma (HCC) stands as the predominant type of primary liver cancer, frequently accompanied by portal vein tumor thrombosis (PVTT). PVTT is a harbinger of a grim prognosis, with current treatment modalities falling short of expectations. Delving deeper into the pathophysiology of PVTT, researchers have come to recognize that PVTT and HCC may originate from different clones. Previous clinical investigations have proposed various PVTT classification systems, offering a scientific basis for individualized and precise treatment. The innovative surgical approach of \"thrombectomy first\" is designed to mitigate the risk of tumor spread, thereby enhancing patient outcomes. Moreover, the multidisciplinary and integrated treatment model, including targeted therapy, immunotherapy and radiotherapy, has demonstrated promising efficacy for the treatment of PVTT. With the continuous progress and optimization of PVTT diagnostic technology, classification systems and precision treatment strategies, the prospects for long-term survival in HCC patients with PVTT are poised to see a significant uplift.</p>","PeriodicalId":60685,"journal":{"name":"中华外科杂志","volume":"63 2","pages":"102-106"},"PeriodicalIF":0.0000,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"中华外科杂志","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3760/cma.j.cn112139-20240910-00419","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Hepatocellular carcinoma (HCC) stands as the predominant type of primary liver cancer, frequently accompanied by portal vein tumor thrombosis (PVTT). PVTT is a harbinger of a grim prognosis, with current treatment modalities falling short of expectations. Delving deeper into the pathophysiology of PVTT, researchers have come to recognize that PVTT and HCC may originate from different clones. Previous clinical investigations have proposed various PVTT classification systems, offering a scientific basis for individualized and precise treatment. The innovative surgical approach of "thrombectomy first" is designed to mitigate the risk of tumor spread, thereby enhancing patient outcomes. Moreover, the multidisciplinary and integrated treatment model, including targeted therapy, immunotherapy and radiotherapy, has demonstrated promising efficacy for the treatment of PVTT. With the continuous progress and optimization of PVTT diagnostic technology, classification systems and precision treatment strategies, the prospects for long-term survival in HCC patients with PVTT are poised to see a significant uplift.

肝癌合并门静脉肿瘤血栓形成的诊治新视角。
肝细胞癌(HCC)是原发性肝癌的主要类型,常伴有门静脉肿瘤血栓(PVTT)。PVTT预示着严峻的预后,目前的治疗方式达不到预期。随着对PVTT病理生理学研究的深入,研究人员已经认识到PVTT和HCC可能起源于不同的克隆。以往的临床研究提出了多种PVTT分类体系,为个体化、精准化治疗提供了科学依据。“先取栓”的创新手术方法旨在降低肿瘤扩散的风险,从而提高患者的预后。此外,包括靶向治疗、免疫治疗和放疗在内的多学科综合治疗模式在PVTT的治疗中显示出良好的疗效。随着PVTT诊断技术、分类体系和精准治疗策略的不断进步和优化,PVTT HCC患者的长期生存前景有望显著提升。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
0.80
自引率
0.00%
发文量
20861
期刊介绍: Chinese Journal of Surgery|Chin J Surg (monthly) is a high-level medical science and technology journal approved by the General Administration of Press and Publication of the People's Republic of China, under the supervision of the China Association for Science and Technology, and organised by the Chinese Medical Association for domestic and international public circulation. It was founded in January 1951, and is published on the basis of the Journal of Chinese Surgery. The Journal is aimed at senior and intermediate surgeons and related researchers, mainly reporting the leading scientific research results and clinical experience in the field of surgery, as well as the basic theoretical research that has a guiding effect on the clinical work of surgery. Chinese Journal of Surgery|Chin J Surg is committed to reflecting the major research progress in the field of surgery in China and promoting academic exchanges at home and abroad. The main columns include thesis, meta-analysis, review, expert forum, synthesis, case report, diagnosis and treatment experience, technical exchange, clinical case discussion, academic controversy, and special lectures, etc. The journal has been accepted by the National Academy of Medicine of the United States. The journal has been included in many famous databases at home and abroad, such as the Biomedical Analysis and Online Retrieval System (MEDLINE) of the U.S. National Library of Medicine.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信